Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

FOXO4-DRI for Men: [Peptide] Comparison

FOXO4-DRI is one senolytic mechanism among several being researched for anti-aging applications. Understanding how it compares to other senolytics and peptide-based interventions clarifies when FOXO4-DRI is the appropriate research tool and when alternative co

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • FOXO4-DRI is one senolytic mechanism among several being researched for anti-aging applications. Understanding how it compares to other senolytics and peptide-based interventions clarifies when FOXO4-DRI is the appropriate research tool and when alternative compounds may be more suitable.
  • FOXO4-DRI
  • p53-FOXO4 disruption induces apoptosis in senescent cells
  • High. Targets p53+ senescent cells specifically
  • 4–6 hours (D-retro-inverso config)
  • Subcutaneous injection
  • Best-in-class for p53-driven senescence; requires lab-grade handling; intermittent dosing only
  • Dasatinib + Quercetin
  • Dasatinib inhibits anti-apoptotic pathways; quercetin inhibits PI3K/AKT survival signaling
  • Moderate. Broader senolytic effect but less selective
  • 3–5 hours (dasatinib); 1–2 hours (quercetin)
  • Oral administration
  • Easier administration; lower cost; less selective than FOXO4-DRI; significant off-target effects
  • Fisetin
  • Activates multiple apoptotic pathways in senescent cells
  • Moderate. Dose-dependent selectivity
  • 45–90 minutes
  • Requires very high doses (20mg/kg+); poor bioavailability; research inconsistent
  • Navitoclax (ABT-263)
  • BCL-2 family inhibitor. Disrupts mitochondrial anti-apoptotic signaling
  • High in BCL-2-dependent senescent cells
  • 17 hours
  • Strong senolytic in preclinical models; thrombocytopenia limits chronic use; research-only status
  • Rapamycin
  • mTOR inhibition reduces SASP without inducing apoptosis
  • Not senolytic. Senomorphic (suppresses SASP secretion)
  • 62 hours
  • Doesn't clear senescent cells; reduces inflammation; well-studied safety profile in humans

Related resources

More comparisons